MedPath
HSA Approval

LENALIDOMIDE-TEVA CAPSULE 15mg

SIN17009P

LENALIDOMIDE-TEVA CAPSULE 15mg

LENALIDOMIDE-TEVA CAPSULE 15mg

May 17, 2024

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

ORAL

Medical Information

L04AX04

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

PLIVA Croatia Ltd.

Active Ingredients

Lenalidomide hydrochloride hydrate eqv. Lenalidomide

15 mg

Proparacaine

Documents

Package Inserts

Lenalidomide-Teva Capsule PI.pdf

Approved: May 17, 2024

Download

Patient Information Leaflets

Lenalidomide-Teva Capsule PIL.pdf

Approved: May 17, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LENALIDOMIDE-TEVA CAPSULE 15mg - HSA Approval | MedPath